You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
譽衡藥業(002437.SZ):一季度淨利潤預增149.27%-174.20%
格隆匯 04-12 18:36

格隆匯4月12日丨譽衡藥業(002437.SZ)公佈2024年第一季度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利5,000.00萬元-5,500.00萬元,比上年同期增長149.27%-174.20%;扣除非經常性損益後的淨利潤盈利3,000.00萬元-3,500.00萬元,比上年同期增長120.76%-157.55%;基本每股收益盈利0.0220元/股-0.0242元/股。

業績變動原因:1、2024年一季度,公司進一步縮減銀行貸款規模,公司財務費用較去年同期有所下降。2、2023年,公司已出售持有的全部廣州譽衡生物科技有限公司(以下簡稱“譽衡生物”)股權,譽衡生物的虧損不再影響公司2024年第一季度損益。3、公司下屬子公司西藏普德醫藥有限公司收到政府補助2,812.69萬元,該事項對公司歸屬於上市公司股東的淨利潤的影響為2,271.25萬元,此部分為非經常性損益。4、2024年一季度,公司持有的WuXi Healthcare Ventures II,L.P.等股權投資產生公允價值變動損益有所下降,預計對歸屬於上市公司股東淨利潤的影響為-1,004萬元,此部分為非經常性損益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account